NOMID

KINERET for NOMID

She’s one of a kind. So is her treatment

KINERET is the first and only FDA-approved treatment for neonatal-onset multisystem inflammatory disease (NOMID).1

Prescribe KINERET

NOMID

Young girl and her mother

NOMID is a rare, predominantly
pediatric autoinflammatory disease2

NOMID can be challenging to diagnose and can cause long-term disability without treatment.2

  • A diagnosis is derived from inflammatory markers, clinical symptoms, severity, and age of onset3,4
  • Symptoms of NOMID include chronic aseptic meningitis, urticaria-like rash, fever, vomiting, joint pain, headache, and conjunctivitis4
  • Over time, chronic inflammation can lead to developmental delay, sensorineural hearing loss, physical disability, and intellectual disability5
  • Although NOMID is often associated with mutations in the CIAS1/NLRP3 gene, approximately 40% of NOMID patients test negative using conventional genetic analyses6
    • 2016 clinical diagnostic criteria for CAPS do not “mandate evidence of a disease-causing NLRP3 mutation”4
NOMID Diagnostic Criteria
NOMID Diagnostic Criteria
Two overlapping squares that are transparent

The degenerative, autoinflammatory nature of NOMID can cause irreversible damage, so early identification is vital.3

Young girl smiling with other girls out of focus

Autoinflammation in NOMID is driven by IL-12

  • IL-1 (IL-1α and IL-1β) is a prototypic proinflammatory cytokine7
    • Secretion of IL-1β has an important role in systemic inflammation and in the signs and symptoms of NOMID1
  • NOMID is often associated with mutations in the CIAS1/NLRP3 gene, which encodes the protein cryopyrin (NLRP3), an important component of the NLRP3 inflammasome8,9,*
    • Although approximately 40% of patients test negative for CIAS1/NLRP3 using conventional genetic analyses, advanced testing techniques have identified somatic NLRP3 mosaicism in ~70% of these patients6
  • A mutation in cryopyrin leads to an increased rate of inflammasome assembly without the necessary inflammatory stimuli3
  • Increased inflammasome activity results in excessive production of the proinflammatory cytokine IL-1β3,8

*A multiprotein complex that activates inflammatory responses.